# Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler

> **NCT00658255** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 175 (estimated)

## Conditions studied

- Stable Asthma

## Interventions

- **DRUG:** budesonide/formoterol
- **DRUG:** formoterol

## Key facts

- **NCT ID:** NCT00658255
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658255, "Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00658255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*